THE NEED FOR A SYSTEM AUDIT IN PHARMACOVIGILANCE CONTRACTING: QPPV PERSPECTIVE
The article argues that a system audit should come before any pharmacovigilance contracting because it gives the QPPV a full understanding of the system they are expected to oversee. By reviewing governance, processes, technology, quality systems, partners, and risks upfront, the audit helps prevent scope creep, budget increases, delays, and compliance gaps.
As Pharmacovigilance Systems become increasingly global, outsourced, and technology-enabled, the role of the Qualified Person for Pharmacovigilance (QPPV) has expanded far beyond regulatory compliance. A QPPV is expected to maintain oversight of complex networks involving Marketing Authorization Holders (MAHs), Contract Research Organizations (CROs), distributors, affiliates, vendors, safety databases, and regulatory authorities. The challenge is that many pharmacovigilance engagements begin with discussions around scope, timelines, and cost before a comprehensive understanding of the client's pharmacovigilance system has been established.
Based on our ongoing work in contracting QPPV services, one observation has become increasingly evident: meaningful scoping cannot occur without first understanding the system. In many cases, the success or failure of a pharmacovigilance engagement is determined long before service delivery begins. It is determined during the initial assessment phase when both the service provider and client seek to understand the true nature, maturity, complexity, and risks of the pharmacovigilance environment. WHO emphasizes that pharmacovigilance is fundamentally a systems-based activity involving processes for detecting, assessing, understanding, and preventing adverse effects and other medicine-related problems.1
This is why I argue that a system audit should be the mandatory first step in pharmacovigilance contracting.
The QPPV’s Unique Accountability
Unlike many outsourced service functions, pharmacovigilance oversight carries significant regulatory and ethical responsibilities.
A QPPV is not merely a contractor providing operational support.
He/she assumes responsibility for maintaining oversight of the pharmacovigilance system and ensuring that safety information is appropriately managed, assessed, escalated, and reported.
EMA's Good Pharmacovigilance Practices (GVP) explicitly positions the Pharmacovigilance System and its Quality System as central components of regulatory compliance. 2
Similarly, the International Society of Pharmacovigilance (ISoP) competency framework identifies the QPPV as the individual responsible for establishing and maintaining a pharmacovigilance system while ensuring regulatory obligations are fulfilled.3 This responsibility extends beyond individual processes and requires a comprehensive understanding of the entire safety ecosystem.
The fundamental question therefore becomes: How can a QPPV accept accountability for a system that has not yet been fully understood?
The Cost of Beginning without a System Audit
Many pharmacovigilance contracts are developed using high-level assumptions regarding the client's products, markets, reporting volumes, quality systems, and operational structure. While such assumptions may facilitate rapid contracting, they often introduce significant risks later in the relationship.
The most immediate consequence is scope creep.
A client may initially request oversight of case management, periodic reporting, and safety governance. However, once activities commence, hidden complexities emerge. These may include undocumented affiliate arrangements, multiple licensing partners, fragmented databases, legacy processes, ongoing remediation activities, or local regulatory obligations that were not previously disclosed.
As the true nature of the system becomes apparent, the contracted scope expands beyond original expectations. Resources increase. Additional expertise becomes necessary. Timelines shift.
Budget creep frequently follows. What appeared to be a routine pharmacovigilance oversight engagement may reveal significant backlog management requirements, inspection findings requiring remediation, incomplete procedural frameworks, or extensive quality system deficiencies. Resources initially budgeted for routine oversight become diverted toward corrective and preventive actions.
The third consequence is delay. Incomplete system understanding often results in prolonged onboarding, slower implementation of governance structures, delayed data reconciliation activities, and challenges in establishing effective oversight mechanisms.
Most concerning, however, is compliance risk! Undetected weaknesses in governance, documentation, reporting pathways, contracts, training records, or computerized systems may remain invisible until identified during a regulatory inspection. Believe it or not, inspection findings expose lapses in the Pharmacovigilance System than the specific observations noted. EMA recognizes quality management, compliance management, documentation, training, and record management as essential components of a compliant pharmacovigilance system. When none of these are instituted and the focus is limited to adverse event collection and reporting, we are actually short- circuiting the entire system.
In many cases, these gaps could have been identified through an initial system audit.
The System Audit as a 360 – Degree Inspection
A pharmacovigilance system audit should not be viewed as a traditional compliance exercise conducted solely to identify deficiencies. Instead, it should be regarded as a structured 360-degree inspection of the client's Pharmacovigilance System.
The objective is to answer a simple but critical question:
What exactly is the QPPV being asked to oversee?
This assessment begins with governance.
An effective system audit examines communication channels, decision-making structures, escalation pathways, and accountability frameworks. It establishes how safety decisions are made and whether responsibilities are clearly assigned.
The audit then explores organizational structure. This includes affiliates, distributors, licensing partners, contract research organizations if applicable and other vendors if available. Pharmacovigilance responsibilities are increasingly distributed across multiple stakeholders, making oversight significantly more challenging.
Process mapping represents another critical element. Case intake, signal management, risk management plans, literature monitoring, aggregate reporting, safety communications, and quality management processes must be reviewed to understand how information flows throughout the organization.
Technology is equally important. Uppsala Monitoring Centre consistently highlights the importance of robust data management systems and standardized information flows in supporting effective pharmacovigilance activities worldwide.4
A system audit should therefore examine databases, reporting tools and interfaces, validation status, access controls, and business continuity arrangements.
Finally, attention must be given to quality systems! Standard operating procedures, deviations, CAPAs, training programs, change controls, inspection history, and compliance monitoring activities provide insight into the maturity and sustainability of the pharmacovigilance system. EMA's GVP Module I, identifies these quality system elements as essential foundations for maintaining effective pharmacovigilance oversight.5
Taken together, these components provide the QPPV with a complete picture of the environment in which they will operate.
From assumptions to Evidence- based Scoping.
One of the greatest benefits of a system audit is its ability to transform assumptions into evidence.
Without an audit, service proposals are often based on estimates. With an audit, they can be based on facts.
The audit enables the development of a realistic resource model, supported by documented workload, system complexity, geographic footprint, product portfolio, and compliance risks. It produces a governance map identifying key stakeholders and responsibilities. It generates a risk register highlighting priority vulnerabilities. Most importantly, it establishes a clearly defined scope that is aligned with operational reality rather than commercial assumptions.
This approach protects both parties.
The client benefits from more accurate budgeting, improved transparency, better inspection readiness, and a clearer understanding of organizational risks. The QPPV benefits from realistic expectations, defined responsibilities, and a stronger foundation for regulatory oversight.
Aligning with Modern Pharmacovigilance Thinking
The argument for system audits is also consistent with broader global trends in pharmacovigilance. WHO's Global Smart Pharmacovigilance Strategy advocates for risk-based approaches, prioritization, resource optimization, and strengthening of pharmacovigilance systems rather than isolated activities.6 The strategy recognizes that sustainable safety oversight depends on understanding where risks reside within systems and directing resources accordingly.
A system audit embodies these principles. It allows organizations to identify critical risks early, allocate resources efficiently, and build oversight models proportionate to actual system complexity.
The pharmacovigilance contract is often viewed as the beginning of a professional relationship. In reality, the system audit should be the true starting point.
Before responsibilities are delegated, budgets approved, or timelines committed, the pharmacovigilance system must be understood in its entirety. A system audit provides this understanding. It offers a 360-degree view of governance structures, operational processes, quality systems, technologies, vendor relationships, and regulatory obligations.
For the QPPV, the audit is not merely a due diligence exercise. It is the mechanism through which accountability becomes possible.
In an environment characterized by increasing regulatory expectations, complex outsourcing arrangements, and growing patient safety responsibilities, pharmacovigilance contracting should begin with a simple principle:
First understand the system. Then define the scope!
REFERENCES
Pharmacovigilance Strategies and Guidelines: Strategies
Pharmacovigilance Systems and their Quality Systems: Guideline on good pharmacovigilance practices (GVP) Module I – Pharmacovigilance systems and their quality systems
ISoP Global QPPV Competency Standards: ISoP Global QPPV Competency Standard v1.0
Strengthening Medicine and Vaccine Safety Systems Worldwide: Uppsala Monitoring Centre | UMC
EMA Good Pharmacovigilance Practices: Guideline on good pharmacovigilance practices (GVP) Module I – Pharmacovigilance systems and their quality systems
Global Smart Pharmacovigilance Strategy (2025): The global smart pharmacovigilance strategy